SUmmARY A hormone-secreting renal tumour that affected small bowel structure, motility, and function has been described by Gleeson et al (1971). The present studies show that the large amount of glucagon-like immunoreactivity which could be extracted from this tumour had the molecular weight, action on plasma insulin and glucose in vivo, and immunological reactions of the gut hormone enteroglucagon. This is the first enteroglucagonoma to be reported.
The development of a radioimmunoassay for glucagon (Unger, Eisentraut, McCall, and Madison, 1961a) led to the unexpected discovery of two sources of glucagon immunoreactivity, one from the pancreas and the other from the gastrointestinal tract (Unger, Eisentraut, Sims, McCall, and Madison, 1961b) . These are released by different physiological stimuli. The peripheral blood level of glucagon-like immunoreactivity was found to rise after oral glucose (Samols, Tyler, Marri, and Marks, 1965) . Using triple-catheter dogs this was shown to be due to material released by the gastrointestinal tract (Unger, Ohneda, Valverde, Eisentraut, and Exton, 1969) . Oral glucose causes a suppression ofpancreatic glucagon release (Unger et al, 1969) . Hypoglycaemia, on the other hand, stimulates the release of pancreatic glucagon and causes a fall in the level of gastrointestinal glucagon-like immunoreactivity (Persson, Gyntelberg, Heding, and Boss-Nielsen, 1971 (Valverde, Rigopoulou, Exton, Ohneda, Eisentraut, and Unger, 1968) . These two forms of enteroglucagon occur throughout the gastrointestinal tract and both are released into the blood stream by oral glucose (Valverde, Rigopoulou, Marco, Faloona, and Unger, 1970 endocrine cell producing enteroglucagon has recently been localized by immunofluorescence and shown to have only minor histological differences from the alpha cell of the pancreas (Polak, Bloom, Coulling, and Pearse, 1971) .
In 1971 Gleeson, Bloom, Polak, Henry, and Dowling described a patient with marked gastrointestinal abnormalities and a renal tumour, which was found to contain cells histologically similar to the pancreatic alpha cells. This tumour was rich in a glucagon-like material and studies will now be described which suggest that the tumour produced enteroglucagon.
Methods
A calibrated 1 metre G 50 Sephadex gel column was used to purify a crude extract of the tumour (supernatant of 20 % w/v saline homogenate) and also to give an approximate molecular weight of the immunoreactivity. Human surgical specimens of ileum and pancreas were extracted by the method of Kenny (1955) for use as standard solutions. A proportion of the ileal extract was purified on the gel column into the larger high molecular weight enteroglucagon and smaller low molecular weight enteroglucagon fractions (Valverde et al, 1968) .
The action in vivo of the tumour material on insulin and glucose release was tested by the intravenous injection into the jugular vein of 200 g Porton rats under nembutal anaesthesia. Crystalline porcine pancreatic glucagon (Novo) was used as a standard.
Antisera were raised in rabbits to pancreatic glucagon polymer (Heding, 1969) and one, RI5, was relatively specific for pancreatic glucagon, crossreacting little with enteroglucagon. Antisera to Sephadex-purified tumour enteroglucagon were raised in two guinea pigs. 520
Pancreatic glucagon and purified tumour extracts were iodinated by the method of Greenwood, Hunter, and Glover (1963) . Immunoassay techniques were based on those described by Albano and Ekins (1970) and employed a charcoal separation.
Results
The main peak of immunoreactivity eluted from the gel column (Fig. 1) coincides with the 7000 molecular weight position. It is identical with the elution volume of the high molecular weight fraction of enteroglucagon from human ileal extracts. A faster moving peak was also present suggesting the presence of some material ofslightly higher molecular weight.
Intravenous injection in the rat of crude tumour extract (the pancreatic glucagon immunoreactive equivalent of 3000 ng per rat) caused a rise of both plasma glucose and insulin. Injection of gel-purified material in more physiological doses (immunoreactive equivalent of 200 ng per rat) produced neither a rise in insulin nor in glucose. The control injection of pancreatic glucagon (80 ng per rat) produced a more rapid and larger rise of both insulin and glucose than the crude tumour injection. It also achieved blood levels of immunoreactive glucagon which were lower than that following injection of gelpurified material (Fig. 2) .
Using an antiserum to pancreatic glucagon, R59, (Gleeson et al, 1971) . The patient's preoperative fasting plasma contained 6000 pg/ml (Gleeson et al, 1971) and postoperatively it contained 400 pg/ml. Immunoassay of the tumour extract, using a relatively specific antipancreatic glucagon antiserum, R15 (Fig. 3) S. R. Bloom creatic glucagon label and this suggests that the material is similar to enteroglucagon.
An antiserum, Gp. R from a guinea pig immunized with tumour, bound iodinated highly purified tumour immunoreactivity (Byfield, Bloom, Dowling, and Maclntyre, 1971 ). This labelled tumour was easily displaced by high molecular weight human ileal enteroglucagon, though much less well by the low molecular weight fraction, and very little by human pancreatic extract. It was also greatly displaced by human plasma samples taken following oral glucose, presumed to have elevated enteroglucagon (Unger et al, 1969) , but not at all by plasma taken during arginine infusion with elevated pancreatic glucagon levels.
Discussion
In this extrapancreatic alpha-cell-like tumour the glucagon immunoreactivity could either have been similar to pancreatic glucagon or to enteroglucagon. Its molecular weight and lack of action on plasma glucose and insulin levels in the rat are both more compatible with it being enteroglucagon. More definite evidence that it is like enteroglucagon is provided by its immunological reactions. It fails to combine with an antiserum which reacts only with pancreatic glucagon. Also, human plasma when it contains enteroglucagon, but not when it contains pancreatic glucagon, is able to prevent the binding of radioactive tumour glucagon to an antiserum to tumour glucagon.
Enteroglucagon is of considerable interest in that it is the only small intestinal peptide hormone whose level can beconfidentlymeasured in peripheral blood. It has been found to be maximally released by actively transported sugars (Unger et al, 1969) . Its actions, however, are not yet established. It has proved so far too labile to purify enough for meaningful administration experiments. Initial suggestions that it caused insulin release have not been substantiated (Marco, Faloona, and Unger, 1971) . The action of low molecular weight enteroglucagon extracts in causing glycogenolysis does not appear to play an important physiological role (Marco et al, 1971) . It has recently been suggested, on circumstantial evidence, that it may inhibit pancreatic bicarbonate output (Dyck, 1971 ).
The patient whose tumour is discussed had several notable intestinal abnormalities, including severe colonic and jejunal stasis, malabsorption, and small intestinal villous hypertrophy (Gleeson et al, 1971) . These abnormalities all disappeared following removal of the tumour, concomitant with the return to normal of the previously elevated plasma enteroglucagon levels. This is the first enteroglucagon-producing tumour to be described and the findings in the patient are probably the best indication so far of the actions of this enigmatic hormone.
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